- Company
- Concurrent reimb review likely for Mounjaro and Ozempic
- by Eo, Yun-Ho Sep 24, 2025 06:25am
- Two anti-obesity drugs that have drawn intense attention may soon undergo reimbursement evaluations for their diabetes indications at the same time. With Novo Nordisk Korea’s Ozempic (semaglutide) already scheduled for review at the upcoming October meeting of the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement E
- Company
- LEO Pharma’s topical JAKi Anzupgo approved in KOR
- by Son, Hyung Min Sep 24, 2025 06:24am
- Global dermatology specialized pharmaceutical company LEO Pharma (General Manager Jung-Bum Shin) announced on the 23rd that its chronic hand eczema treatment Anzupgo (delgocitinib) was officially approved by the Ministry of Food and Drug Safety on the 8th. With the approval, adult patients in Korea suffering from moderate-to-severe chroni
- Company
- Sanofi begins nationwide supply of flu vaccine Vaxigrip
- by Son, Hyung Min Sep 23, 2025 06:07am
- Sanofi announced on the 22nd that it has begun nationwide supply of its trivalent influenza vaccine Vaxigrip from September 3rd, ahead of the 2025&8211;2026 flu vaccination season. According to the Korea Disease Control and Prevention Agency’s analysis of influenza surveillance results for the 2024&8211;2025 season, last year’s flu ep
- Company
- ‘Reimb needed for Ozempic, a powerful weapon for diabetes’
- by Hwang, byoung woo Sep 23, 2025 06:07am
- Diabetes treatment has moved beyond blood glucose control and entered the era of “personalized strategies,” With the Korean Diabetes Association’s 2025 clinical guidelines removing the long-standing recommendation of metformin as the first-line therapy and instead advising initial treatment based on patient characteristics and comorbiditi
- Company
- Bylvay successfully obtains reimbursement on the 2nd attempt
- by Moon, sung-ho Sep 23, 2025 06:06am
- Bylvay (odeviksibab), a treatment for Progressive Familial Intrahepatic Cholestasis (PFIC), will be included in the National Health Insurance reimbursement program starting next month. As a high-cost medication for a severe and rare disease, Bylvay's reimbursement and monitoring have been categorized under government management. Accordi
- Company
- Rising childhood obesity in Korea’s limited environment
- by Eo, Yun-Ho Sep 22, 2025 06:11am
- The need for active management of childhood and adolescent obesity is becoming increasingly emphasized, along with growing interest in the appropriate use of pharmacotherapy. According to the ‘2020 Clinical Practice Guidelines of the Korean Society for the Study of Obesity,’ childhood obesity treatment in Korea primarily focuses on li
- Company
- "Long-term survival possible for urothelial carcinoma"
- by Son, Hyung Min Sep 22, 2025 06:11am
- The treatment landscape for urothelial carcinoma is changing rapidly. Various approaches, including immunotherapy, antibody-drug conjugates (ADCs), and chemotherapy combination therapies, have been introduced. However, significant reimbursement barriers still exist in clinical practice. Among these, Merck's Bavencio (avelumab) is the only fir
- Company
- NMOSD patients call for Ultomiris’s reimbursement
- by Hwang, byoung woo Sep 22, 2025 06:11am
- With the emergence of an innovative treatment option for neuromyelitis optica spectrum disorder (NMOSD), a disease in which even one relapse can cause a dramatic decline in quality of life, voices are growing for improved access. Specifically, voices are rising on the need to improve access to Ultomiris (ravulizumab), which has demonstrated
- Company
- Reimb discussions begin for No.2 GIFT drug Nefecon
- by Eo, Yun-Ho Sep 22, 2025 06:10am
- Reimbursement discussions have begun for Nefecon (budesonide), the second drug designated under Korea’s GIFT (Global Innovative products on Fast Track) program and the first treatment for IgA nephropathy. According to industry sources, the Health Insurance Review and Assessment Service (HIRA) is expected to soon begin evaluation of the
- Company
- "List of competing companies for obesity mkt half-finished"
- by Kim, Jin-Gu Sep 22, 2025 06:10am
- Following Novo Nordisk's signing of a co-promotion agreement with Chong Kun Dang for the obesity treatment 'Wegovy (semaglutide),' attention in the pharmaceutical industry has turned to which company will partner with Eli Lilly for the co-promotion of its rival product, 'Mounjaro (tirzepatide).' The pharmaceutical industry anticipate th
